Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

[1] Turnbull FM(2009)Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288-2298

[2] Abraira C(2019)Glycaemic variability in diabetes: clinical and therapeutic implications The lancet Diabetes & endocrinology 7 221-230

[3] Anderson RJ(2019)Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort Cardiovasc Diabetol. 18 170-2365

[4] Byington RP(2014)Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial Diabetes Care 37 2359-2194

[5] Chalmers JP(2018)Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial Diabetes Care 41 2187-57

[6] Duckworth WC(2018)Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) Diabetologia 61 48-28

[7] Ceriello A(2014)Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME) Cardiovasc Diabetol 13 102-1907

[8] Monnier L(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med. 373 2117-217

[9] Owens D(2018)Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control Circulation 138 1904-493

[10] Slieker RC(2020)Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial Eur Heart J 41 209-2637

[1] Turnbull FM(2009)Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2288-2298

[2] Abraira C(2019)Glycaemic variability in diabetes: clinical and therapeutic implications The lancet Diabetes & endocrinology 7 221-230

[3] Anderson RJ(2019)Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort Cardiovasc Diabetol. 18 170-2365

[4] Byington RP(2014)Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial Diabetes Care 37 2359-2194

[5] Chalmers JP(2018)Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial Diabetes Care 41 2187-57

[6] Duckworth WC(2018)Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) Diabetologia 61 48-28

[7] Ceriello A(2014)Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME) Cardiovasc Diabetol 13 102-1907

[8] Monnier L(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med. 373 2117-217

[9] Owens D(2018)Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control Circulation 138 1904-493

[10] Slieker RC(2020)Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial Eur Heart J 41 209-2637